INCYTE CORP (INCY)
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
📈 **POSITIVE** • High confidence analysis (92%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business